Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
US Raises Concerns Over Possible ASML EUV Machine Transfer to China 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Qantas Nears Launch of World’s Longest Non-Stop Flights to London and New York 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
HSBC Australia Faces A$35M Penalty Over Scam Protection Failures 
Trump Says Anthropic No Longer Seen as National Security Threat 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
GAITHERSBURG, Md., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that management will present at the 34th Annual J.P. Morgan Healthcare Conference.
Presentation details are as follows:
Date: Wednesday, January 13, 2016
Time: 11:30 am PT
Location: Elizabethan Room B, Westin St. Francis Hotel, San Francisco
Live webcast: http://jpmorgan.metameetings.com/confbook/healthcare16/directlink?p=20196
The webcast and replay of the presentation will also be accessible under the “Investors/Events” section of the website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.
Contact: Novavax, Inc.
Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer
Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations
[email protected]
240-268-2000
Russo Partners, LLC
David Schull
Todd Davenport, Ph.D.
[email protected]
[email protected]
212-845-4271
